BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 40.39% | 11.90% | -56.96% | 2.94% | -90.57% |
| Total Depreciation and Amortization | -1.88% | 0.95% | -43.58% | 2.75% | 7.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -77.21% | -43.71% | 2,389.55% | -71.49% | -31.49% |
| Change in Net Operating Assets | -76.14% | 1,295.87% | -75.65% | 129.30% | -466.31% |
| Cash from Operations | -41.54% | 59.13% | -47.33% | 57.25% | -4,129.55% |
| Capital Expenditure | -- | 100.00% | -100.00% | 43.75% | -128.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -100.00% | 43.75% | -128.57% |
| Total Debt Issued | 23.52% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Debt Repaid | -4.81% | 25.10% | 59.09% | 9.35% | -67.44% |
| Issuance of Common Stock | 400.78% | -86.36% | 6.83% | -64.40% | 488.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 895.43% | -92.22% | 409.98% | -90.81% | 10,568.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 149.23% | -598.21% | 90.34% | -209.03% | 2,184.31% |